{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-24-000119","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.818864+00:00","generated_at":"2026-05-30T05:27:07.255235+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tarsus appoints Elizabeth Yeu as CMO; she resigns from board","bullets":["Dr. Yeu appointed Chief Medical Officer effective Nov 4, 2024; resigned from Board same date.","Annual base salary of $480,000, $25,000 signing bonus, and 45% annual incentive bonus.","Granted 27,278 RSUs vesting 25% annually over four years, and option for 41,074 shares.","Severance includes 12 months salary and benefits; accelerated vesting on change in control.","Dr. Yeu previously served as board member since Dec 2021 and consulting Chief Medical Advisor."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-24-000119","json":"https://secwatch.observer/filing/0001819790-24-000119.json","markdown":"https://secwatch.observer/filing/0001819790-24-000119.md","text":"https://secwatch.observer/filing/0001819790-24-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/tars-20241101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:27:07.255235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f0200862c","claim":"Elizabeth Yeu was appointed as Chief Medical Officer at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"On November 5, 2024, Tarsus Pharmaceuticals, Inc. (the \"Company\") announced the appointment of Elizabeth Yeu, M.D. as the Company's Chief Medical Officer, effective as of November 4, 2024 (the \"Effective Date\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"53cc6378e1","claim":"Elizabeth Yeu resigned as Member of the Board of Directors at Tarsus Pharmaceuticals, Inc..","evidence_excerpt":"In connection with the appointment, on November 1, 2024, Dr. Yeu resigned as a member of the Company's board of directors (the \"Board\") and from the committees of the Board on which she served, each effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}